PCN85 Comparison of Observed LONG-TERM Overall Survival with Extrapolated Overall Survival for Pembrolizumab Monotherapy Assessed By Australian Reimbursement Authorities

Autor:	K. Phan, Charles Taylor, C. Spiteri, F. Dehle, M. Bohensky, E. Toomeh
Rok vydání:	2020
Předmět:	Oncology medicine.medical_specialty business.industry Health Policy Internal medicine Economics Econometrics and Finance (miscellaneous) medicine Overall survival Pembrolizumab business Pharmacology Toxicology and Pharmaceutics (miscellaneous) Reimbursement Term (time)
Zdroj:	Value in Health Regional Issues. 22:S21
ISSN:	2212-1099
DOI:	10.1016/j.vhri.2020.07.135
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::dc3a3e247b609f1060dd7c27e659f7fc https://doi.org/10.1016/j.vhri.2020.07.135 Zobrazit plný text záznamu Full Text from ScienceDirect